Biotech analyst joins Forward Pharma as CFO
This article was originally published in Scrip
Executive Summary
Copenhagen, Denmark-based Forward Pharma, a biopharmaceutical company focused on a proprietary formulation of dimethyl fumarate for the treatment of multiple sclerosis, has named Joel Sendek chief financial officer. Mr Sendek joins Forward Pharma from Stifel Financial where he was managing director, biotechnology, and led the firm's healthcare equity research group. Mr Sendek will serve as a key member of the executive team providing strategic leadership for the company's financial functions, and for its short and long-term financial objectives in support of the business strategy, Forward Pharma said.
You may also be interested in...
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.